Evaluation of a Third and Fourth Dose of StaphVAX® in Adults With End-Stage Renal Disease

PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

December 31, 2005

Study Completion Date

April 30, 2006

Conditions

Staphylococcal InfectionsChronic Kidney Failure

Interventions

BIOLOGICAL

Staph aureus types 5 and 8 conjugate vaccine

each IM dose contains 200 mc total conjugate

BIOLOGICAL

placebo

placebo to match StaphVAX

Trial Locations (1)

multiple sites: contact Central Study coordination, Birmingham